Navamedic ASA (OSL:NAVA)

Market Cap	534.78M
Revenue (ttm)	539.42M
Net Income (ttm)	-37.89M
Shares Out	23.98M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	18.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,130
Average Volume	5,655
Open	21.20
Previous Close	22.30
Day's Range	21.20 - 21.40
52-Week Range	17.10 - 28.40
Beta	0.19
RSI	47.43
Earnings Date	Apr 29, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.